Trial Summary

Taking Part

Who? Men with newly diagnosed locally advanced or metastatic prostate cancer
When? The trial is open now
Where? Hospitals throughout the UK and Switzerland (STAMPEDE map)

This study is called STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) and looks at the effect of adding new or different treatments to the standard way in which prostate cancer is currently managed.

This study aims to improve the way in which prostate cancer is currently managed and enable men to live longer and enjoy a better quality of life.

Many different treatments have been tested in the trial which originally opened in 2005. The trial is current recruiting patients to help answer two questions:

  1. Can the addition of metformin (an anti-diabetic treatment) help prevent the side effects of hormone treatment and enable men affected by prostate cancer to live longer?
  2. Can an alternative form of hormone therapy given as a patch instead of injections or tablets (called transdermal oestradiol) treat prostate cancer as effectively but avoid some of the side effects of standard hormone therapy?

The trial is funded by the charities Cancer Research UK, Prostate Cancer UK and the pharmaceutical companies; Sanofi-Aventis, Pfizer, Novartis, Jansen, Astellas, Clovis and the Medical Research Council.
If you are interested in taking part please talk to your medical team, the map above shows all of the hospitals taking part in the trial.